What MariTide is and who makes it
MariTide, whose medicine name is maridebart cafraglutide, is Amgen's injection being studied for dosing once a month or less often. It joins an antibody to two peptides: it activates the GLP-1 receptor and blocks the GIP receptor. That differs from Mounjaro, which activates both.
Trial stage and published results
The published results come from a 52-week phase 2 trial of 592 adults, published in The New England Journal of Medicine in 2025. In people with obesity without type 2 diabetes, Amgen reports average weight loss of 12.3% to 16.2% across the MariTide doses against 2.5% with placebo, counting everyone who started treatment. Counting only people while they stayed on treatment, the figures were 16.3% to 19.9% against 2.6%. These are trial averages, not a prediction for any one person.
Amgen says vomiting was common at the higher doses and that lower starting doses improved digestive side effects. It began the phase 3 MARITIME programme of 72-week weight-management trials in 2025.
Sources: NEJM: MariTide phase 2 trial (2025); Amgen: MariTide phase 2 results at ADA, June 2025.
EU and Irish regulatory status
MariTide is not authorised by any regulator. The EMA's list of new medicines under evaluation, with data extracted on 5 October 2026, has no entry for maridebart cafraglutide, and we found no announced application in the EU, the US or the UK.
When could it be available in Ireland?
A new weight-loss medicine like this reaches Irish prescribers through the European Medicines Agency. The EMA says its committee's scientific assessment takes up to 210 active days, not counting the pauses while the company answers questions, and the European Commission then decides within 67 days of the committee's opinion. A company launch and pharmacy stock in Ireland come after that.
Our estimate, not a company date: the 72-week phase 3 trials still have to finish and report before any EU application, so availability through an Irish prescriber before 2029 looks unlikely. Amgen has not published a filing or launch date; the real date is UNKNOWN.
Sources: EMA: obtaining an EU marketing authorisation, step by step.
What about websites selling it now?
No authorised version of MariTide exists, so a product sold online under this name is not an approved medicine and may contain anything. We do not list these sellers or their prices. Read the HPRA's warning about buying medicines online.
What people in Ireland can use now
Authorised GLP-1 medicines for weight management, such as Wegovy and Mounjaro, are prescription-only and are prescribed after a clinical assessment. Our guide to getting a GLP-1 prescription in Ireland explains the routes, and the eligibility check shows which ones may fit your BMI and health. Neither offers access to MariTide.